Autologous stem cell therapy - Biotech Holdings

Drug Profile

Autologous stem cell therapy - Biotech Holdings

Alternative Names: Microbiome optimized autologous stem cells - Biotech Holdings; ProCell activated stem cells - Biotech Holdings

Latest Information Update: 30 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biotech Holdings
  • Class Antineoplastics; Cardiovascular therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Hepatocyte growth factor modulators; Immunosuppressants; Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Peripheral vascular disorders
  • Preclinical Autoimmune disorders

Most Recent Events

  • 25 Oct 2017 Biotech Holdings and Biorasi agree to co-develop stem cell therapy for critical limb ischaemia
  • 16 Oct 2017 Biotech Holdings files for patent protection with the USPTO for Reverse abscopal effect with ProCell activated stem cell therapy in USA
  • 16 Oct 2017 Preclinical trials in Autoimmune disorders in USA (Parenteral) before October 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top